Tempest Therapeutics Inc
TPST3.120USD
+0.140+4.70%
收盘 12/19, 16:00（美东）报价延迟15分钟
13.85M总市值
亏损市盈率 TTM
关于 Tempest Therapeutics Inc 公司
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Tempest Therapeutics Inc简介
公司代码TPST
公司名称Tempest Therapeutics Inc
上市日期Oct 04, 2012
CEO- -
员工数量24
证券类型Ordinary Share
年结日Oct 04
公司地址2000 Sierra Point Parkway
城市BRISBANE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94005
电话14157988589
网址https://www.tempesttx.com/
公司代码TPST
上市日期Oct 04, 2012
CEO- -
Tempest Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
+1.29%
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
666.00
-0.15%
Mr. Michael (Mike) Raab
Mr. Michael (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Dr. Ronit Simantov, M.D.
Dr. Ronit Simantov, M.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
+1.29%
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
666.00
-0.15%
Mr. Michael (Mike) Raab
Mr. Michael (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Dr. Ronit Simantov, M.D.
Dr. Ronit Simantov, M.D.
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 12月6日 周六
更新时间: 12月6日 周六
持股股东
股东类型
持股股东
持股股东
占比
Versant Ventures
5.48%
The Vanguard Group, Inc.
3.30%
Geode Capital Management, L.L.C.
0.83%
BlackRock Institutional Trust Company, N.A.
0.79%
Fidelity Management & Research Company LLC
0.67%
其他
88.93%
持股股东
持股股东
占比
Versant Ventures
5.48%
The Vanguard Group, Inc.
3.30%
Geode Capital Management, L.L.C.
0.83%
BlackRock Institutional Trust Company, N.A.
0.79%
Fidelity Management & Research Company LLC
0.67%
其他
88.93%
股东类型
持股股东
占比
Venture Capital
5.48%
Investment Advisor
5.46%
Investment Advisor/Hedge Fund
0.87%
Research Firm
0.12%
Individual Investor
0.11%
其他
87.97%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
71
871.05K
19.62%
-32.43K
2025Q2
71
462.14K
11.78%
-326.50K
2025Q1
72
466.15K
11.99%
-315.34K
2024Q4
74
6.85M
15.70%
-2.07M
2024Q3
64
6.40M
25.40%
-2.51M
2024Q2
60
6.46M
29.08%
-2.26M
2024Q1
57
6.17M
27.79%
-2.56M
2023Q4
58
6.52M
33.89%
-1.52M
2023Q3
54
8.53M
66.99%
-219.33K
2023Q2
55
8.95M
101.95%
+3.83M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Versant Ventures
162.97K
3.67%
-106.80K
-39.59%
Aug 11, 2025
The Vanguard Group, Inc.
134.61K
3.03%
+111.69K
+487.45%
Jun 30, 2025
Geode Capital Management, L.L.C.
34.74K
0.78%
+1.40K
+4.21%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
39.07K
0.88%
-3.84K
-8.95%
Jun 30, 2025
Fidelity Management & Research Company LLC
33.23K
0.75%
-1.00
-0.00%
Jun 30, 2025
UBS Financial Services, Inc.
11.22K
0.25%
-13.68K
-54.93%
Jun 30, 2025
Brady (Stephen R)
3.61K
0.08%
+46.00
+1.29%
Apr 09, 2025
Morgan Stanley Smith Barney LLC
2.11K
0.05%
+49.00
+2.38%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Apr 07, 2025
Merger
13→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
公告日期
类型
比率
Apr 07, 2025
Merger
13→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
常见问题
Tempest Therapeutics Inc的前五大股东是谁？
Tempest Therapeutics Inc 的前五大股东如下：
Versant Ventures持有股份：162.97K，占总股份比例：3.67%。
The Vanguard Group, Inc.持有股份：134.61K，占总股份比例：3.03%。
Geode Capital Management, L.L.C.持有股份：34.74K，占总股份比例：0.78%。
BlackRock Institutional Trust Company, N.A.持有股份：39.07K，占总股份比例：0.88%。
Fidelity Management & Research Company LLC持有股份：33.23K，占总股份比例：0.75%。
Versant Ventures持有股份：162.97K，占总股份比例：3.67%。
The Vanguard Group, Inc.持有股份：134.61K，占总股份比例：3.03%。
Geode Capital Management, L.L.C.持有股份：34.74K，占总股份比例：0.78%。
BlackRock Institutional Trust Company, N.A.持有股份：39.07K，占总股份比例：0.88%。
Fidelity Management & Research Company LLC持有股份：33.23K，占总股份比例：0.75%。
Tempest Therapeutics Inc的前三大股东类型是什么？
Tempest Therapeutics Inc 的前三大股东类型分别是：
Versant Ventures
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
Versant Ventures
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
有多少机构持有Tempest Therapeutics Inc(TPST)的股份？
截至2025Q3，共有71家机构持有Tempest Therapeutics Inc的股份，合计持有的股份价值约为871.05K，占公司总股份的19.62%。与2025Q2相比，机构持股有所增加，增幅为7.84%。
哪个业务部门对Tempest Therapeutics Inc的收入贡献最大？
在--，--业务部门对Tempest Therapeutics Inc的收入贡献最大，创收--，占总收入的--%。
